Andrew Moreno

DocwireNews

Two active Investigational New Drug (IND) applications from Atara Biotherapeutics, Inc., have been placed on clinical hold by the FDA, Atara announced in a press release.The clinical hold concerns Atara&rsquo;s program on tabelecleucel monotherapy for Epstein-Barr virus (EBV)&ndash;positive post-transplant lymphoproliferative disease (PTLD) in adult and pediatric patients aged two years and older. The treatment is being developed by Atara as Ebvallo.At a third-party manufacturing facility for Ebvallo, referenced in the Ebvallo Complete Response Letter (CRL) released on January 16, 2025, Good Manufacturing Practice (GMP) compliance issues were identified during the prelicense inspection. The FDA implemented the clinical hold on Ebvallo due to these issues having not been sufficiently addressed.Also affected by the clinical hold is Atara&rsquo;s program for ATA3219, an allogeneic CD19-targeted chimeric antigen receptor (CAR) T-cell therapy to treat non-Hodgkin lymphoma and systemic lupus erythematosus. ATA3219 and Ebvallo are manufactured at different facilities and the ATA3219 site is GMP-compliance&ndash;certified but the base materials for ATA3219 production are affected by the compliance issues at the third-party facility cited in the Ebvallo CRL.The issues leading to the clinical hold from the FDA refer only to the third-party manufacturing facility cited in the CRL. They do not pertain to the FUJIFILM Diosynth Biotechnologies facility in Thousand Oaks, California, another third-party manufacturing site used by Atara.For the two Atara programs under the FDA clinical hold, screening and enrollment of new participants for clinical studies is currently paused. However, participants already enrolled who might clinically benefit from these investigation therapies may continue to receive them in keeping with the ongoing study protocols.Atara is working with the FDA to quickly resolve the issues which led to the hold&rsquo;s implementation.&ldquo;We are encouraged with ongoing correspondence with the Agency and a potential path to submitting the necessary data to release the clinical hold. Patient safety remains our priority and maintaining the highest standards for our programs,&rdquo; stated Atara President and Chief Executive Officer Cokey Nguyen, PhD.ReferenceAtara Biotherapeutics provides update on clinical programs related to Ebvallo&trade; (tabelecleucel) and ATA3219. Press Release. <a href="https://investors.atarabio.com/news-events/press-releases/detail/368/atara-biotherapeutics-provides-update-on-clinical-programs">Atara Biotherapeutics. January 21, 2025.</a> Accessed January 23, 2025.

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

FDA: Tabelecleucel Monotherapy, Anti-CD19 CAR T-Cell Therapy INDs Placed on Clinical Hold

Hematology

Two therapies being developed for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus are affected.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe